Establishment of the active catalytic domain of human PDGFRβ tyrosine kinase-based ELISA assay for inhibitor screening

Biochimica et Biophysica Acta - General Subjects

Volumn 1770, Issue 10, 2007, Pages 1490-1497

  Zhang, Xiu Hua ^a   Guo, Xiao Ning ^a   Zhong, Li ^a   Luo, Xiao Min ^b   Jiang, Hua Liang ^b   Lin, Li Ping ^a   Ding, Jian ^a  

^a State Key Laboratory of Medical Genomics   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bac to Bac system; PDGFR ; TKI 30; Tyrosine kinase inhibitors

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (2 FLUOROPHENYLAMINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; SUNITINIB; TKI 30; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN; VASCULAR SMOOTH MUSCLE;

ANIMALS; CATALYTIC DOMAIN; CELL LINE; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MAGNESIUM; MANGANESE; MOTHS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS;

EID: 34548587167     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.06.017     Document Type: Article

References (27)

1. Coltrera M.D., Wang J., Porter P.L., and Gown A.M. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res. 55 (1995) 2703-2078
2. Dabrow M.B., Francesco M.R., McBrearty F.X., and Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol. Oncol. 71 (1998) 29-37
3. Hofer M.D., Fecko A., Shen R., Setlur S.R., Pienta K.G., Tomlins S.A., Chinnaiyan A.M., and Rubin M.A. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6 (2004) 503-512
4. Lafuente J.V., Adan B., Alkiza K., Garibi J.M., Rossi M., and Cruz-Sanchez F.F. Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J. Mol. Neurosci. 13 (1999) 177-185
5. Lindmark G., Sundberg C., Glimelius B., Pahlman L., Rubin K., and Gerdin B. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab. Invest. 69 (1993) 682-689
6. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R.K., Heldin C.H., and Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61 (2001) 2929-2934
7. Board R., and Jayson G.C. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist. Updates 8 (2005) 75-83
8. Heldin C.H., Eriksson U., and Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. 398 (2002) 284-290
9. Heldin C.H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79 (1999) 1283-1316
10. Betsholtz C., Karlsson L., and Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 23 (2001) 494-507
11. Mologni L., Sala E., Riva B., Cesaro L., Cazzaniga S., Redaelli S., Marin O., Pasquato N., Donella-Deana A., and Gambacorti-Passerini C. Expression, purification, and inhibition of human RET tyrosine kinase. Protein Expr. Purif. 41 (2005) 177-185
12. Bohlin K., Olsson L., and Cotgreave I.A. The isolation, culture and characterisation of human smooth muscle cells from umbilical vein and their reconstitution into a functional syngenetic co-culture model with endothelial cells. Methods Cell Sci. 18 (1996) 329-341
13. Mendel D.B., Laird A.D., Xin X.H., Louie S.G., Christensen J.G., Li G.M., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., and Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
14. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. New colorimetric cytotoxicity assay for anti-cancer drug screening. J. Natl. Cancer Inst. 82 (1990) 1107-1112
15. Racker E. Use of synthetic amino-acid polymers for assay of protein-tyrosine and protein-serine kinases. Method. Enzymol. 200 (1991) 107-111
16. Guo X.N., Zhong L., Zhang X.H., Zhao W.M., Zhang X.W., Lin L.P., and Ding J. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim. Biophys. Acta 1673 (2004) 186-193
17. Zhong L., Guo X.N., Zhang X.H., Wu Z.X., Luo X.M., Jiang H.L., Lin L.P., Zhang X.W., and Ding J. Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening. Biochim. Biophys. Acta 1722 (2005) 254-261
18. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., and Wood E.R. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains - demonstration of differential sensitivity to kinase inhibitors. J. Biol. Chem. 277 (2002) 1576-1585
19. Heldin C.H., Ostman A., and Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1378 (1998) F79-F113
20. Guo P., Hu B., Gu W., Xu L., Wang D., Huang H.J., Cavenee W.K., and Cheng S.Y. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162 (2003) 1083-1093
21. Abramsson A., Lindblom P., and Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112 (2003) 1142-1151
22. Sawutz D.G., Bode D.C., Briggs G.M., Reid J.R., Canniff P., Caldwell L., Faltynek C.R., Miller D., Dunn J.A., de Garavilla L., Guiles J.W., Weigelt C., Michne W., and Treasurywala A.M. In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem. Pharmacol. 51 (1996) 1631-1638
23. Pietras K., Rubin K., joblom T.S., Buchdunger E., joquist M.S., Heldin C.H., and Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62 (2002) 5476-5484
24. Wei L., Hubbard S.R., Hendrickson W.A., and Ellis L. Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain. J. Biol. Chem. 270 (1995) 8122-8130
25. Zhuang S.F., Zhou C.H., Qian J., Qian Z., Shibuya M., and Ye Q.Z. A new model for random screening inhibitors of vascular endothelial growth factor receptor 1 kinase. Acta Pharmacol. Sin. 23 (2002) 117-123
26. Guo X.N., Zhong L., Tan J.Z., Li J., Luo X.M., Jiang H.L., Nan F.J., Lin L.P., Zhang X.W., and Ding J. In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects. Cancer Biol. Ther. 4 (2005) 1125-1132
27. Zhong L., Guo X.N., Zhang X.H., Sun Q.M., Tong L.J., Wu Z.X., Luo X.M., Jiang H.L., Nan F.J., Zhang X.W., Lin L.P., and Ding J. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta. Cancer Biol. Ther. 5 (2006) 323-330